It also scrapped plans to float its HIV drug business ViiV Healthcare, citing its strong outlook, and promised to pay a steady dividend of 80 pence a share over the next three years. Chief Executive Andrew Witty is under pressure to prove to investors that a $20 billion-plus asset swap with Novartis can revive GSK's fortunes, following a damaging slide in lung drug sales and a major corruption scandal in China.